OncoSpherix News & Events
OncoSpherix Named Finalist for 2025 BIO International Convention Start-Up Stadium
May 13, 2025 Emerging oncology innovator OncoSpherix to showcase breakthrough cancer therapies at global biotech stage in Boston Atlanta, GA — May 2025 — OncoSpherix, a pre-clinical-stage oncology company advancing novel therapies for unresectable and metastatic...
OncoSpherix Selected to Present at Portal Innovations’ ‘Rising Stars in Oncology’ Event During AACR 2025
April 22, 2024 OncoSpherix to Showcase Breakthrough Oncology Innovations at Premier Biotech Event Atlanta, GA – Apr 2025 – OncoSpherix, a biotech company pioneering innovative therapies for tumor hypoxia, is excited to announce its participation in Portal Innovations’...
OncoSpherix Relocates to Portal Innovations’ State-of-the-Art Life Sciences Facilities, Poised for Next Stage of Growth
November 20, 2024 OncoSpherix Becomes a Portal Innovations Member Company Atlanta, GA – Nov 2023 – OncoSpherix,, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors for a variety of cancer indications, is excited to announce its recent...
OncoSpherix Showcased at 2024 Georgia Bio Life Sciences Summit, Highlights Latest Advances in Cancer treatment
November 18, 2024 OncoSpherix Participates in Annual Georgia Life Sciences Summit Atlanta, GA – Nov 18, 2024 – OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors for a variety of cancer indications, proudly participated in...
OncoSpherix expands its operations team with the appointment of Joseph Ellis, Ph.D., as Research Scientist
Oct 1, 2024 Joseph Ellis, Ph.D., joins OncoSpherix’s Research Team Atlanta, GA – Oct 1, 2024 – OncoSpherix, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors in variety of cancer indications, announces the appointment of Joseph Ellis,...
OncoSpherix Presents at Biopharma Drug Discovery Nexus East Coast 2023 in Philadelphia on Wednesday, October 18 at 9:45 AM.
October 16, 2023 Atlanta, GA – October 16, 2023 – The CEO of OncoSpherix, Inc, Dr. Margaret K. Offermann, MD, PhD, is delivering a keynote address at Biopharma Drug Discovery Nexus East Coast 2023 in Philadelphia on Wednesday, October 18 at 9:45 AM. Her presentation...
OncoSpherix expands leadership team with the appointment of Allan Valmonte, M.B.A., as Vice President of Business Operations
April 28, 2023 Allan Valmonte, M.B.A., former Executive Director, Program Management Office (PMO) at Taysha Gene Therapies, joins OncoSpherix with over 25 years of program/portfolio management and clinical operations experience in the biotechnology and pharmaceutical...
OncoSpherix expands leadership team with the appointment of Steve Coats, Ph.D. as Vice President of Chemistry
April 28, 2023 Dr. Steve Coats, former Senior Director of Chemistry at Cocrystal Pharma, joins OncoSpherix with over 25 years of drug discovery and development experience in biotechnology and large pharmaceutical companies. Atlanta, GA – April 28, 2023 – OncoSpherix,...
OncoSpherix to Present Data from its Hypoxia Inducible Factor (HIF) Inhibitor 64B in Uveal Melanoma
April 12, 2023 64B is a small molecule therapeutic that inhibits the function of hypoxia inducible factors (HIFs) 64B given systemically inhibits primary tumor growth and metastases 64B was far superior to either sunitinib or selumetinib at causing a regression in...
OncoSpherix CEO to Serve as Keynote Speaker at 5th Meridian Drug Discovery Conference in Boston on Tuesday, November 8, 2022
The 5th Meridian Drug Discovery Conference will be held at the Embassy Suites by Hilton at Boston Longan Airport on November 7-8, 2022. Dr. Margaret Offermann will present a keynote address entitled "Mechanism Matters: Overcoming Past Failures in Developing HIF...